A jury ordered Johnson & Johnson to pay $1.8 million to a Maryland man who developed female breasts while taking the company's Risperdal antipsychotic drug, the third verdict in thousands of lawsuits filed over the side effect. Johnson & Johnson officials failed to properly warn doctors and patients that Risperdal, used to treat schizophrenia and bipolar disorder, could spark abnormal male breast development, a state court jury in Philadelphia concluded Monday.